Haemonetics Corporation (HAE)
Haemonetics Statistics
Share Statistics
Haemonetics has 50.24M shares outstanding. The number of shares has increased by -1.4% in one year.
| Shares Outstanding | 50.24M |
| Shares Change (YoY) | -1.4% |
| Shares Change (QoQ) | 0.03% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | 49.68M |
| Failed to Deliver (FTD) Shares | 3 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is 4.43M, so 8.82% of the outstanding shares have been sold short.
| Short Interest | 4.43M |
| Short % of Shares Out | 8.82% |
| Short % of Float | 13.95% |
| Short Ratio (days to cover) | 4.93 |
Valuation Ratios
The PE ratio is 36.81 and the forward PE ratio is 12.71. Haemonetics's PEG ratio is 16.71.
| PE Ratio | 36.81 |
| Forward PE | 12.71 |
| PS Ratio | 3.31 |
| Forward PS | 2 |
| PB Ratio | 4.51 |
| P/FCF Ratio | 37.48 |
| PEG Ratio | 16.71 |
Enterprise Valuation
Haemonetics has an Enterprise Value (EV) of 4.96B.
| EV / Sales | 3.79 |
| EV / EBITDA | 18.66 |
| EV / EBIT | 27.27 |
| EV / FCF | 42.93 |
Financial Position
The company has a current ratio of 2.56, with a Debt / Equity ratio of 0.84.
| Current Ratio | 2.56 |
| Quick Ratio | 1.5 |
| Debt / Equity | 0.84 |
| Debt / EBITDA | 3.04 |
| Debt / FCF | 7 |
| Interest Coverage | 12.67 |
Financial Efficiency
Return on Equity is 12.25% and Return on Invested Capital is 6.7%.
| Return on Equity | 12.25% |
| Return on Assets | 5.35% |
| Return on Invested Capital | 6.7% |
| Revenue Per Employee | $357.96K |
| Profits Per Employee | $32.15K |
| Employee Count | 3,657 |
| Asset Turnover | 0.6 |
| Inventory Turnover | 1.95 |
Taxes
| Income Tax | 34.31M |
| Effective Tax Rate | 22.59% |
Stock Price Statistics
The stock price has increased by -32.41% in the last 52 weeks. The beta is 0.41, so Haemonetics's price volatility has been higher than the market average.
| Beta | 0.41 |
| 52-Week Price Change | -32.41% |
| 50-Day Moving Average | 63.13 |
| 200-Day Moving Average | 74.3 |
| Relative Strength Index (RSI) | 54.67 |
| Average Volume (20 Days) | 951.29K |
Income Statement
In the last 12 months, Haemonetics had revenue of 1.31B and earned 117.56M in profits. Earnings per share was 2.32.
| Revenue | 1.31B |
| Gross Profit | 691.55M |
| Operating Income | 164.88M |
| Net Income | 117.56M |
| EBITDA | 265.58M |
| EBIT | 164.88M |
| Earnings Per Share (EPS) | 2.32 |
Balance Sheet
The company has 178.8M in cash and 807.79M in debt, giving a net cash position of -628.99M.
| Cash & Cash Equivalents | 178.8M |
| Total Debt | 807.79M |
| Net Cash | -628.99M |
| Retained Earnings | 360.46M |
| Total Assets | 2.53B |
| Working Capital | 752.63M |
Cash Flow
In the last 12 months, operating cash flow was 181.75M and capital expenditures -66.3M, giving a free cash flow of 115.45M.
| Operating Cash Flow | 181.75M |
| Capital Expenditures | -66.3M |
| Free Cash Flow | 115.45M |
| FCF Per Share | 2.28 |
Margins
Gross margin is 52.83%, with operating and profit margins of 12.6% and 8.98%.
| Gross Margin | 52.83% |
| Operating Margin | 12.6% |
| Pretax Margin | 11.6% |
| Profit Margin | 8.98% |
| EBITDA Margin | 20.29% |
| EBIT Margin | 12.6% |
| FCF Margin | 8.82% |
Dividends & Yields
HAE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 2.72% |
| FCF Yield | 2.67% |
Analyst Forecast
The average price target for HAE is $104, which is 64.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $104 |
| Price Target Difference | 64.9% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
Stock Splits
The last stock split was on Dec 3, 2012. It was a forward split with a ratio of 2:1.
| Last Split Date | Dec 3, 2012 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 2.55 |
| Piotroski F-Score | 6 |